title: AIB1 as an independent prognostic marker in hepatocellular carcinoma after hepatic resection.
abstract: BACKGROUND
  Amplified in breast cancer 1 (AIB1) has been shown to promote growth and invasion in several types of human cancers and to have a prognostic role in some of cancers. However, its prognostic significance in hepatocellular carcinoma (HCC) remains unknown. This study aimed to address the issue.
  
  
  METHODS
  Immunohistochemical staining of AIB1 was performed for HCC and paired paratumorous liver (PTL) tissues from 139 patients. Associations between AIB1 expression with clinicopathological variables and patient survival were evaluated.
  
  
  RESULTS
  The expression rate of AIB1 was significantly higher in HCC (71/139, 51.1%) than in PTL tissues (1/139, 0.72%, P < 0.001). AIB1 expression in HCC was significantly associated with serum α-fetoprotein levels (P = 0.001) and Edmondson-Steiner grade (P = 0.038). Higher AIB1 expression in HCC was associated with shorter cumulative overall survival of the patients. Multivariate Cox regression analysis revealed that AIB1 was of independent prognostic significance for HCC.
  
  
  CONCLUSIONS
  AIB1 is independently associated with poor prognosis of HCC.
authors: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Hepatic, Biliary, and Pancreatic Surgery Unit I, Peking University School of Oncology, Beijing Cancer Hospital and Institute, 52 Fu Cheng Road, Beijing, 100142, China.
authors: Jun-Min
authors: JM
authors: Song
authors: Min
authors: M
authors: Lu
authors: Fang-Fang
authors: FF
authors: Liu
authors: Xiao-Juan
authors: XJ
authors: Du
authors: Bao-Cai
authors: BC
authors: Xing
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism*; D006528:Carcinoma, Hepatocellular / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006498:Hepatectomy; D006801:Humans; D007150:Immunohistochemistry; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology / Q000601:surgery; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D056921:Nuclear Receptor Coactivator 3 / Q000378:metabolism*; D011379:Prognosis; D016019:Survival Analysis; D015996:Survival Rate; D000509:alpha-Fetoproteins / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D000509:alpha-Fetoproteins; C538866:NCOA3 protein, human; D056921:Nuclear Receptor Coactivator 3